| 8.03 Delayed Data As of Jun 14 |  -0.33 / -3.95%Today’s Change | 3.60 Today|||52-Week Range 25.77 | +25.08% Year-to-Date |
| DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade Jun 12 / Zacks.comZAK - Paid Partner Content | DBV Technologies to Attend Upcoming Investor Conferences Jun 03 / GlobeNewswirePNW - Paid Partner Content |
| Monthly information regarding the total number of voting rights and total number of ... Jun 11 / GlobeNewswirePNW - Paid Partner Content | DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Mee... May 24 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 8.36 |
| Today’s open | 8.29 |
| Day’s range | 7.99 - 8.29 |
| Volume | 309,202 |
| Average volume (3 months) | 295,216 |
| Market cap | $580.7M |
| Earnings growth (last year) | -0.59% |
| Earnings growth (this year) | -41.81% |
| Earnings growth (next 5 years) | +35.50% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 3.50 |
| Today’s change | Today’s % change | |
|---|---|---|
| --Oxford BioMedica PLC | -0.10 | -1.19% |
| CLXTCalyxt Inc | -0.10 | -0.77% |
| BSTCBiospecifics Technol... | -1.56 | -2.70% |
| CDXSCodexis Inc | -0.10 | -0.57% |
| Last reporting date | March 6, 2019 |
| EPS forecast (this quarter) | -$0.82 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$195.9M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Executive Director Daniel Tassé |
Chief Financial Officer & Deputy CEO David S. Schilansky |
Corporate headquarters Montrouge, Ile-de-france |
